Aripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism

Basit Öğe Kaydı
dc.contributor.authorBaykal, Saliha
dc.contributor.authorMutlu, Caner
dc.date.accessioned2023-05-06T17:22:13Z
dc.date.available2023-05-06T17:22:13Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractObjectivesThis report discusses the emergence, clinical appearance, and treatment of the rare entity Capgras syndrome (CS) in an adolescent diagnosed with autism.MethodsAfter a brief introduction to the CS, we conduct a detailed description of the case and review, after a search on the PubMed database, the known pathophysiology, psychiatric disorders associated with the onset of this syndrome, and the management of CS.ResultsCapgras syndrome generally emerges during the course of delusional disorder, schizophrenia, or mood disorders, and for reasons such as neurological, infectious, or endocrinological diseases, drug intoxications, or deprivation. We encountered no previous reports of CS developing during the course of autism. There are no prospective studies concerning the treatment of the syndrome. However, antipsychotic drug use is primarily recommended in treatment. Antipsychotic drug therapy was therefore planned for the treatment of delusion, a psychotic symptom, in this case. The atypical antipsychotic aripiprazole was used based on the presence of accompanying diagnosis of autism, and the patient's body mass index and age. A relatively high dose of aripiprazole was required for the first psychotic attack in our patient. However, a good level of response was achieved within the expected time frame. In addition, no marked adverse effects were observed.ConclusionsAripiprazole seems to be an effective and well-tolerated antipsychotic drug in the treatment of CS accompanying autism.
dc.identifier.doi10.1097/WNF.0000000000000536
dc.identifier.endpage86
dc.identifier.issn0362-5664
dc.identifier.issn1537-162X
dc.identifier.issue2en_US
dc.identifier.pmid36728844
dc.identifier.scopus2-s2.0-85150181574
dc.identifier.scopusqualityQ3
dc.identifier.startpage85
dc.identifier.urihttps://doi.org/10.1097/WNF.0000000000000536
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12119
dc.identifier.volume46
dc.identifier.wosWOS:000949015000009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBaykal, Saliha
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofClinical Neuropharmacology
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectautism
dc.subjectCapgras syndrome
dc.subjectaripiprazole
dc.subjectcase report
dc.subjectChildhood Autism
dc.subjectSchizophrenia
dc.titleAripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu